Evidence map›Paper›PMID 33197626›Full record

ArticleNanomedicine : nanotechnology, biology, and medicine2021

A novel liposome-polymer hybrid nanoparticles delivering a multi-epitope self-replication DNA vaccine and its preliminary immune evaluation in experimental animals.

Zhangting Zhao, Xingyuan Ma, Ruihuan Zhang, Fabiao Hu, Tong Zhang, Yuping Liu, Myong Hun Han, Fang You, Yi Yang, Wenyun Zheng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine : nanotechnology, biology, and medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Research Progress on Liposome Pulmonary Delivery ofJournal of aerosol medicine and pulmonary drug delivery · 2024
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zhangting ZhaoState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, PR China.
Xingyuan MaState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, PR China.
Ruihuan ZhangState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, PR China.
Fabiao HuState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, PR China.
Tong ZhangShanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, PR China.
Yuping LiuShanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, PR China.
Myong Hun HanState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, PR China; Department of Genetics, Faculty of Life Science, KIM IL SUNG University, Pyongyang, Democratic People's Republic of Korea.
Fang YouDepartment of Chemical and Biomolecular Engineering, National University of Singapore, Singapore 117585, Singapore.
Yi YangSinGENE Biotech Pte Ltd, Singapore Science Park, Singapore 118258, Singapore. Electronic address: yangyi@singenebio.com.
Wenyun ZhengShanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, PR China. Electronic address: zwy@ecust.edu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

DNA vaccine is an attractive immune platform for the prevention and treatment of infectious diseases, but existing disadvantages limit its use in preclinical and clinical assays, such as weak immunogenicity and short half-life. Here, we reported a novel liposome-polymer hybrid nanoparticles (pSFV-MEG/LNPs) consisting of a biodegradable core (mPEG-PLGA) and a hydrophilic shell (lecithin/PEG-DSPE-Mal 2000) for delivering a multi-epitope self-replication DNA vaccine (pSFV-MEG). The pSFV-MEG/LNPs with optimal particle size (161.61 ± 15.63 nm) and high encapsulation efficiency (87.60 ± 8.73%) induced a strong humoral (3.22-fold) and cellular immune responses (1.60-fold) compared to PBS. Besides, the humoral and cellular immune responses of pSFV-MEG/LNPs were 1.58- and 1.05-fold than that of pSFV-MEG. All results confirmed that LNPs was a very promising tool to enhance the humoral and cellular immune responses of pSFV-MEG. In addition, the rational design and delivery platform can be used for the development of DNA vaccines for other infectious diseases.

Indexed as

DNA ReplicationEpitopesVaccines, DNAAnimalsImmunity, CellularImmunity, HumoralLiposomesMiceMice, Inbred BALB CNanoparticlesEpitopesLiposomesVaccines, DNADeliveryDNA vaccineImmune evaluationInfectious diseasesLiposome-polymer hybrid nanoparticles

Identifiers

PMID33197626
PMCPMC7664365

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.